Bexarotene
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Alogliptin
Dipeptidyl peptidase-4 (DPP-4) inhibitor · Antidiabetic
START
25 mg PO once daily (12.5 mg if eGFR 30–59; 6.25 mg if eGFR <30)
TYPICAL MAX
25 mg/day
STOP IF
Pancreatitis, severe hypersensitivity (SJS/angioedema), or heart failure decompensation
WATCH
Renal function, signs of HF/pancreatitis, severe joint pain
CDSCO approvedSchedule HATC A10BH04
KDIGO 2024 + manufacturer label
- ONSET
- 30min · absorption
- PEAK
- 1.5h · Tmax
- t½
- 21h · t½
- DURATION
- 1d · once-daily
EXCRETION
Renal — ~76% unchanged
route + CYP
INTERACTIONS
2 major
SEVERE in our sources
PREGNANCY
Insulin preferred in pregnancy; use only if benefit outweighs risk.
FDA category + note
Top interactions
- BexaroteneSevereDatabaseDDInter
- GatifloxacinSevereDatabaseDDInter
Mechanism
Selective reversible inhibitor of DPP-4, prolonging the half-life of endogenous incretins (GLP-1, GIP) — enhances glucose-dependent insulin secretion and suppresses glucagon, lowering postprandial and fasting glucose with low intrinsic hypoglycaemia risk.
Indications
Type 2 diabetes mellitus (mono- or combination)
Dosing
- Adult
- 25 mg PO once daily (with or without food).
- Pediatric
- Not established.
- Renal adjustment
- CrCl 30–59: 12.5 mg/day. CrCl <30 / ESRD: 6.25 mg/day.
- Hepatic adjustment
- Severe hepatic impairment: not studied — caution.
- Geriatric
- No specific adjustment beyond renal function.
- Max dose
- 25 mg/day
Pharmacokinetics
Onset
Glucose lowering over days
Peak effect
~1–2 h (Tmax)
Duration
~24 h (once-daily)
Half-life
~21 h
Bioavailability
~100%
Protein binding
~20%
Metabolism
Minimal hepatic (mostly excreted unchanged)
Excretion
Renal (~76% unchanged)
Contraindications
- Severe hypersensitivity (including SJS, angioedema)
- Caution: history of pancreatitis, severe heart failure (alogliptin specifically has a HF signal)
Side effects
Common
NasopharyngitisHeadacheUpper respiratory infectionHypoglycaemia (mainly with insulin/sulfonylureas)
Serious
- Acute pancreatitis
- Severe hypersensitivity (SJS, anaphylaxis, angioedema)
- Hepatotoxicity
- Heart failure (alogliptin/saxagliptin class concern)
- Severe joint pain
Pregnancy & lactation
Pregnancy
Insulin preferred in pregnancy; use only if benefit outweighs risk.
Lactation
Limited data; weigh benefit/risk.
Drug interactions
Gatifloxacin
Severe
Database
Drug interaction classified as: antagonism
Source: DDInter
10 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Heart failure in diabetes
RSSDI · Cardiology · 2023
Gestational diabetes mellitus
FOGSI · Obstetrics & Gynaecology · 2023
Dyslipidaemia in diabetes
RSSDI · Endocrinology · 2022
Fluid and electrolyte management in diabetes
RSSDI · Endocrinology · 2025
Diabetes management during Ramadan
ADA · Endocrinology · 2025
Ask House about Alogliptin
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20